Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Open-Label Study of ABT-450 + ritonavir and ABT-267 in Chronic Hepatitis C Infection (Spain)
2011-005762-38Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paritaprevir, glecaprevir and ritonavir in chronic hepatitis C (CHC) (5 arms), sponsored by Abbott Laboratories. Primary endpoint: Primary SVR12 comparison Groups 1 vs 2 and 4 vs 5. Started May 2012; status: completed.
02
Drugs
paritaprevirglecaprevirritonavir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2011-005762-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005762-38.